未经证实:神经母细胞瘤是儿童时期最常见的颅外实体瘤,来自交感神经系统。尽管加强了治疗,但高风险神经母细胞瘤(HRNB)仍然是一个主要的治疗挑战,生存率低。这项研究旨在开发一种恶性细胞标记基因标签(MMGS),该标签可能作为HRNB患者的预后指标。
未经评估:多组数据集,包括mRNA表达(单细胞和散装),DNA甲基化,和HRNB患者的临床信息,用于鉴定预后恶性细胞标记基因。MMGS是通过单变量Cox分析建立的,拉索,和逐步多变量Cox回归分析。采用Kaplan-Meier(KM)曲线和时间依赖性受试者工作特征曲线(tROC)评价MMGS的预后价值和性能,分别。MMGS在独立验证集中进一步验证了其可靠性和准确性。最后,功能富集的特点,肿瘤免疫特征,我们还调查了不同MMGS风险组之间的炎症活动。
UNASSIGNED:我们构建了一个由六个恶性细胞标记基因组成的预后模型(MAPT,C1QTNF4,MEG3,NPW,RAMP1和CDT1),将患者分为超高危(UHR)和普通高危(CHR)组。UHR组患者的总生存期(OS)明显低于CHR组。MMGS被证实是HRNB患者OS的独立预测因子。MMGS的曲线下面积(AUC)值在1-,3-,和5年期分别为0.78、0.693和0.618。值得注意的是,功能富集,肿瘤免疫特征,和炎症活性分析初步表明,UHR组的不良预后可能是由于代谢过程和免疫抑制微环境的失调所致。
UNASSIGNED:本研究建立了一种新型的六恶性细胞标志物基因预后模型,可用于预测HRNB患者的预后,这可能为HRNB患者的治疗和个性化监测提供新的见解。
UNASSIGNED: Neuroblastoma is the most common extracranial solid tumor of childhood, arising from the sympathetic nervous system. High-risk neuroblastoma (HRNB) remains a major therapeutic challenge with low survival rates despite the intensification of therapy. This study aimed to develop a malignant-cell marker gene signature (MMGS) that might serve as a prognostic indicator in HRNB patients.
UNASSIGNED: Multi-omics datasets, including mRNA expression (single-cell and bulk), DNA methylation, and clinical information of HRNB patients, were used to identify prognostic malignant cell marker genes. MMGS was established by univariate Cox analysis, LASSO, and stepwise multivariable Cox regression analysis. Kaplan-Meier (KM) curve and time-dependent receiver operating characteristic curve (tROC) were used to evaluate the prognostic value and performance of MMGS, respectively. MMGS further verified its reliability and accuracy in the independent validation set. Finally, the characteristics of functional enrichment, tumor immune features, and inflammatory activity between different MMGS risk groups were also investigated.
UNASSIGNED: We constructed a prognostic model consisting of six malignant cell maker genes (MAPT, C1QTNF4, MEG3, NPW, RAMP1, and CDT1), which stratified patients into ultra-high-risk (UHR) and common-high-risk (CHR) group. Patients in the UHR group had significantly worse overall survival (OS) than those in the CHR group. MMGS was verified as an independent predictor for the OS of HRNB patients. The area under the curve (AUC) values of MMGS at 1-, 3-, and 5-year were 0.78, 0.693, and 0.618, respectively. Notably, functional enrichment, tumor immune features, and inflammatory activity analyses preliminarily indicated that the poor prognosis in the UHR group might result from the dysregulation of the metabolic process and immunosuppressive microenvironment.
UNASSIGNED: This study established a novel six-malignant cell maker gene prognostic model that can be used to predict the prognosis of HRNB patients, which may provide new insight for the treatment and personalized monitoring of HRNB patients.